They've done really well bringing the R&D spend down to focus on getting DX1 to trials with the cash they have. At this level, including staff and corporate costs, they've got 5 quarters of cash to fund operations. The R&D spend will still increase when they get back into production this quarter and ramp up towards trials, but they may have avoided needing a raise for now. I'd expect they might try and get a raise off the back of potentially positive news flow such as a successful production run and launch of the clinical trial (2H CY2024). If they hadn't paused DX3 work, it'd be a completely different picture.
PAB Price at posting:
0.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)